PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1501234
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1501234
The preclinical imaging market is projected to reach USD 1,259 million by 2029 from USD 946 million in 2024, at a CAGR 5.9% during the forecast period. The market growth is mainly driven by factors such as increasing market demand for new drug development and noninvasive small-animal imaging techniques, growing number of public-private initiatives and funding to support preclinical researches, technological advancements in the field of molecular imaging, and development of low-cost & affordable preclinical imaging systems.
Scope of the Report | |
---|---|
Years Considered for the Study | 2018-2029 |
Base Year | 2023 |
Forecast Period | 2024-2029 |
Units Considered | Value (USD) Million |
Segments | Product Type, Application, End User, and Region |
Regions covered | North America, Europe, APAC, LATAM, MEA |
"Optical Imaging System accounted for the largest share of the market in the forecast period, by product type."
Based on product, the preclinical imaging market is segmented into imaging systems, reagents, and software. The imaging systems is further segmented into optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic imaging, and magnetic particle imaging. The optical imaging segment captured the largest market share, primarily due to its extensive application in small animal imaging and new drug discovery projects. Several factors have contributed to the growing adoption of optical preclinical imaging. Technological advancements in molecular imaging have significantly enhanced the field, offering researchers more sophisticated and precise imaging capabilities.
"Oncology segment accounted for the largest share of the market in the forecast period, by application."
Based on application, the preclinical imaging market is segmented into oncology, cardiology, neurology, infectious diseases, immunology and inflammation, and other applications. Among the preclinical imaging applications, oncology holds the largest share. This can be due to several factors such as preclinical imaging enables researchers to track tumor progression and treatment response in the same animal over time. This is particularly valuable in oncology for assessing the effectiveness of new drugs and therapies.
"The pharmaceutical and biotechnology companies segment accounted for the largest share of the market in the forecast period, by end user."
Based on end user, the preclinical imaging market is segmented into pharmaceutical & biotechnology companies, academic and research centers, imaging centers, and other end users. The pharmaceutical & biotechnology companies segment accounted for the largest share during the forecast period. The demand for preclinical imaging in biotech companies has been steadily rising in recent years and is projected to continue growing. This increasing market demand in pharmaceutical and biotech companies is driven by the spread of emerging and re-emerging infectious diseases. Preclinical imaging is essential for gaining a better understanding of pathogens and for aiding the development of new therapeutics and vaccines.
"Asia Pacific to register the highest growth in the preclinical imaging market in the forecast period."
The global preclinical imaging market is segmented into five major regions, namely, North America, Europe, APAC, Latin America, and Middle East & Africa. In 2023, Asia Pacific was expected to register the highest growth for preclinical imaging market in the forecast period. Factors such as lower research costs, less stringent regulatory guidelines, and increased government funding for the development of the research and development sector in these countries are making the region attractive for preclinical research studies. Consequently, the clinical research outsourcing (CRO) industry is thriving in emerging countries like China and India.
The prominent players in this market are Bruker Corporation (US), Revvity, Inc. (US), MR Solutions (UK), Mediso Ltd. (UK), Trefoil Imaging (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GMBH & CO.KG (Germany), Sofie (US), Viewworks (Korea), AI4R (France), Kub Technologies (US), Medikor (US), and Miltenyi Biotech GmbH (Germany) . Players adopted organic as well as inorganic growth strategies such as new product launches, acquisitions, and expansions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Research Coverage
The report studies the preclinical imaging market based on product type, application, end user, and region. The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total brain computer interface market. The report forecasts the revenue of market segments with respect to five major regions.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.